<DOC>
	<DOCNO>NCT00166309</DOCNO>
	<brief_summary>FENOC prospective , open-label , randomize , cross-over , multi-center study investigate compare hemostatic effect cost-efficacy two different by-passing agent treatment joint hemorrhage subject severe hemophilia A inhibitor . The study design clinical equivalency trial .</brief_summary>
	<brief_title>The FEIBA NovoSeven Comparative Study</brief_title>
	<detailed_description>The incidence inhibitor among people severe hemophilia A documented approximately 20-30 % several prospective study . In patient acute hemorrhage frequently occur profoundly jeopardize health , subsequent development arthropathy . A common way treat bleed episode use bypass agent . Among agent prothrombin complex concentrate FEIBA widely use many year . More recently , recombinant factor VIIa ( NovoSeven ) add therapeutic option . While product find effective treating hemorrhage , number injection give bleed episode range widely , far unknown whether one product might better effect certain patient .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Congenital hemophilia A inhibitor need bypass agent case joint bleeding . An expected bleeding frequency &gt; =3 joint bleeds per year . Informed consent give . Age two old . Other congenital acquire bleed disorder . Symptomatic liver disease . Life expectancy &lt; 12 month .</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Inhibitors</keyword>
</DOC>